Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of ...
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field today There are approximately 130,000 people living with ER+ metastatic breast cancer in …